#Australia #Perth #Cancer Surgery #Ziva Surgical #ELORA System

Ziva Surgical: Revolutionizing Breast Cancer Surgery

In a significant development for breast cancer treatment, OncoRes Medical has rebranded itself as Ziva Surgical. This transformation not only includes a new name and visual identity but also represents a pivotal moment in the company's mission to redefine how solid tumor cancers are diagnosed and treated during surgery. Based out of Perth, Australia, Ziva Surgical has spent over a decade perfecting its technology, focusing on providing real-time tissue intelligence that can greatly improve surgical outcomes.

The journey began with a small, dedicated team in Perth who aimed to tackle a major challenge in cancer surgery: how to confirm in real-time whether cancerous tissue remains after surgery. Building upon extensive research and innovation in quantitative micro-elastography (QME)—primarily developed at the University of Western Australia and the Harry Perkins Institute of Medical Research—OncoRes has evolved into Ziva Surgical. This progression has led to the creation of their groundbreaking product, the ELORA® System.

Traditionally, surgeons have relied on their sense of sight, touch, and clinical judgment to determine the necessity of further tissue removal during procedures. However, these methods often fall short, sometimes leaving behind residual cancer that could lead to more surgeries. Ziva Surgical's ELORA® System aims to enhance this decision-making process by providing quantitative maps of tissue characteristics, specifically stiffness and microarchitecture, directly inside the surgical cavity. By translating tactile sensations into objective data, ELORA® can help surgeons make more informed choices about what tissue to remove or preserve during an operation, thus potentially reducing the need for subsequent surgeries.

To date, about 20% of women who undergo breast-conserving surgery experience the anxiety and disruption of a second operation to address residual cancer. The innovative technology underlying the ELORA® System has received FDA Breakthrough Device Designation, acknowledging its potential to improve patient outcomes significantly. With more than 44 patents globally across ten patent families, Ziva Surgical is equipped to realize its vision of delivering real-time tissue intelligence to enhance surgical accuracy.

As they progress towards commercialization, Ziva Surgical's CEO, Dr. Katharine Giles, remarked, "This evolution marks an incredibly exciting moment for our company and reflects how far we've come from our beginnings in Perth. We've spent over a decade translating pioneering research into a technology with the potential to meaningfully change the way surgeons make decisions in the operating room."

Ziva Surgical is not just limited to breast cancer; their long-term ambitions extend to other types of solid tumors, such as prostate cancer, where early trials have indicated promising results. As they embark on this new chapter, their primary mission remains clear: to arm surgeons with better tools that grant essential clarity during operations, ultimately helping more patients recover successfully, often after just one surgery.

For more information about Ziva Surgical and the innovative ELORA® System, please visit zivasurgical.com. The future of breast cancer surgery is here—and it's promising.